Literature DB >> 16045835

Treatment advances in psoriatic arthritis.

Eric M Ruderman1.   

Abstract

Treatment of psoriatic arthritis, like the treatment of rheumatoid arthritis, now commonly includes the use of inhibitors of tumor necrosis factor in addition to traditional synthetic disease-modifying antirheumatic drugs. This paper examines the most recent data from therapeutic trials in psoriatic arthritis, with particular emphasis on the effectiveness of the tumor necrosis factor inhibitors. Recent data on potential future therapies is discussed as well, along with data on the mechanisms of current therapies that may have relevance for future treatment approaches.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16045835     DOI: 10.1007/s11926-005-0042-7

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  41 in total

1.  Treatment of psoriatic arthritis with granulocyte and monocyte adsorption apheresis.

Authors:  Takuro Kanekura; Hisashi Kawabata; Ikuro Maruyama; Tamotsu Kanzaki
Journal:  J Am Acad Dermatol       Date:  2004-02       Impact factor: 11.527

2.  The treatment of enthesitis in psoriatic arthritis.

Authors:  Namita Kumar; Lesley J Kay; David J Walker
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

3.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.

Authors:  Gerald G Krueger; Kim A Papp; Dow B Stough; Keith H Loven; Wayne P Gulliver; Charles N Ellis
Journal:  J Am Acad Dermatol       Date:  2002-12       Impact factor: 11.527

4.  A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.

Authors:  A D Fraser; A W R van Kuijk; R Westhovens; Z Karim; R Wakefield; A H Gerards; R Landewé; S D Steinfeld; P Emery; B A C Dijkmans; D J Veale
Journal:  Ann Rheum Dis       Date:  2004-11-04       Impact factor: 19.103

5.  Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.

Authors:  A Y Goedkoop; M C Kraan; M B M Teunissen; D I Picavet; M A de Rie; J D Bos; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

6.  Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis.

Authors:  Juan D Cañete; José L Pablos; Raimon Sanmartí; Carmen Mallofré; Sara Marsal; Joan Maymó; Jordi Gratacós; Jovita Mezquita; Cristobal Mezquita; Maria C Cid
Journal:  Arthritis Rheum       Date:  2004-05

7.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06

8.  Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects.

Authors:  K Takada; C L Danning; T Kuroiwa; R Schlimgen; I O Tassiulas; J C Davis; C H Yarboro; T A Fleisher; D T Boumpas; G G Illei
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

9.  Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection.

Authors:  J R Peterson; F C Hsu; P A Simkin; M H Wener
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

10.  Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study.

Authors:  Amber Y Goedkoop; Maarten C Kraan; Daisy I Picavet; Menno A de Rie; Marcel B M Teunissen; Jan D Bos; Paul P Tak
Journal:  Arthritis Res Ther       Date:  2004-05-26       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.